MEDICINAL CHEMISTRY STRATEGY MEETING SAN DIEGO 2021

May, 25th Tuesday, 2021 Hard Rock Hotel San Diego



MEDICINALCHEMISTRY

Click here to find out what our clients think about our STRATEGY MEETINGS

OUR VISION

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

OUR MISSION

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

OUR UNIQUE MEETING FORMAT

Roundtable Discussions
These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

Personalised Agenda
Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.

One-to-one Meetings
The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

Strategic Networking
Strategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

CONTRIBUTORS TO THE AGENDA

Uli Schmitz
Executive Director, Structural Chemistry
Gilead Sciences

Paul Galatsis
VP, Chemistry
Vibliome Therapeutics

Mike Petrassi
VP, Medicinal Chemistry
Calibr/Scripps Research

Prasun Mishra
CEO
Agility Pharmaceuticals

Bill Shirley
Senior Director, Structural Chemistry
Gilead Sciences

Tudor Oprea
Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine
Univeristy of New Mexico

Syed Askari
CEO and Founder
Maculus Therapeutics

Robert Hilgraf
Senior Director, Medicinal Chemistry
REVOLUTION Medicines

OUR SPONSORS

ASSOCIATE SPONSOR

药明康德 WuXi AppTec

Visit Website

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated.

CO-HOST SPONSORS

CDD VAULT®
COLLABORATIVE DRUG DISCOVERY

Visit Website

Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological study data and chemical structures, and to collaborate with partners through a straightforward web interface.

Nanome

Visit Website

Nanome, the first virtual reality (VR) software company to launch an immersive real-time collaboration platform for scientific discovery, is changing the way we understand and interact with science at the molecular level. The software environment allows users to visualize, modify, and simulate proteins, chemical compounds, and nucleic acids to accelerate scientific decision making. The platform facilitates effective communication of data and integrates with existing computational chemistry workflows—features that have led to the adoption of the San Diego–based company's enterprise solution by several pharmaceutical and biotech companies worldwide. For more information, visit nanome.ai

KEY OPINION LEADER

NovAliX

Visit Website

AGENDA

TRACK & ROOM (TIME)	01 - ARTIFICIAL INTELLIGENCE / MACHINE LEARNING	02 - CHEMICAL BIOLOGY & CHEMINFORMATICS	03 - DESIGN & CUSTOM SYNTHESIS	04 - HIT TO LEAD IDENTIFICATION	05 - INTEGRATED DRUG DISCOVERY
08:00 - 08:30	REGISTRATION AND WELCOME				
08:30 - 09:00	OPENING KEYNOTE PANEL SESSION **Assessing the COVID-19 Impact on Drug Discovery in Medicinal Chemistry: The Industry Priorities for 2021?** • Weighing the pros and cons of rapid global therapy development to strategize for lost time and improve efficiency in 2021 and beyond • How we utilize data integration from multiple sources to accelerate progress • Evaluating the costs & benefits of emerging technologies • Explore new opportunities for research and funding in 2021				
09:00 - 10:00	Evaluating the impact of AI generative methods and ML models in drug discovery **Uli Schmitz —** *Executive Director, Structural Chemistry,* Gilead Sciences	Shifting away from the single-target paradigm: linking pharmacological data with biological pathways via high-throughput computational methods **Mike Petrassi —** *VP, Medicinal Chemistry,* Calibr/Scripps Research	Optimizing autonomy in synthesis: discussing the current state and outlook towards better efficiency **Syed Askari —** *President & CEO,* Maculus Therapeutix	Novel strategies to balancing high-throughput capabilities with multi-parametric studies	Partnering and Licensing with an Academic Medical Center **Peter Kotsonis & Ellen Kats, Ph.D (Co-host) —** *Executive Director, Office of Strategic Alliances,* UCSF & *Assistant Director, Business Development & Licensing,* UCSF
10:00 - 11:00	**10:00 - 10:20:** NETWORKING / 1-1 MEETINGS		**10:20 - 10:40:** NETWORKING / 1-1 MEETINGS		**10:40 - 11:00:** NETWORKING / 1-1 MEETINGS
11:00 - 12:00	药明康德 WuXi AppTec	CDD VAULT® COLLABORATIVE DRUG DISCOVERY	Furthering the new paradigm: the marriage of robotics and advanced analytics in drug design Topic TBC for Sponsor	Nanome	Advancing cycle time, analysis and purification efficiency through novel technologies and innovative approaches Topic TBC for Sponsor
12:00 - 13:00	NETWORKING LUNCH				
13:00 - 13:30	KEYNOTE PRESENTATION				
13:30 - 14:30	Beyond the AI hype: What has worked, and what will be improved in the future? **Bill Shirley —** *Senior Director, Structural Chemistry,* Gilead Sciences	Leveraging DNA-encoded libraries and cheminformatics to discover novel reactions and chemistries	How does the target integrate with the clinical side? What can we do to ensure success in the clinic? **Paul Galatsis —** *VP, Chemistry,* Vibliome Therapeutics	Computational Methods for Hit to Lead Optimization - how do we prioritize good from bad? **David Wustrow —** *Vice President, Discovery,* RAPT Therapeutics	Effective Integration of Multidisciplinary Teams to Ensure Seamless Drug Discovery Processes **Yuhua Ji —** *Head of Medicinal Chemistry,* Zai Lab US
14:30 - 15:30	**14:30 - 14:50:** NETWORKING / 1-1 MEETINGS		**14:50 - 15:10:** NETWORKING / 1-1 MEETINGS		**15:10 - 15:30:** NETWORKING / 1-1 MEETINGS
15:30 - 16:30	Leveraging AI and ML to extract value from large, disparate, internal/external data sets to aid drug discovery Topic TBC for Sponsor	Improving CADD capacities: moving past classical AI and ML towards the quantum age Topic TBC for Sponsor	Innovative design & development steps to optimise outsourcing speed, reliability and cost Topic TBC for Sponsor	Delineating the pros and cons of molecular dynamics simulations in fragment-based drug design Topic TBC for Sponsor	Optimising early drug discovery through harmonised DDI testing, genetic heterogeneity and PK data analysis Topic TBC for Sponsor
16:30 - 17:00	**16:30 - 16:50:** NETWORKING / 1-1 MEETINGS			**16:50 - 17:00:** BREAK	
17:00 - 18:00	Beyond the Hype of New Machine Learning Technology and Onto Delivery **Tudor Oprea —** Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine, University of New Mexico	Evaluating the challenges surrounding obtaining and structuring the right data sets **Katherine Matsumoto —** *Director, Product Management,* Recursion Pharmaceuticals	Novel computational approaches to design next gen drugs keeping optimized scale up and yield in mind	Targeting Protein-Protein Interactions (PPIs) – Challenges and Technologies **Robert Hilgraf —** *Senior Director, Medicinal Chemistry,* REVOLUTION Medicines	Reinstating phenotypic screening in your drug discovery workflow: discover novel phenotypes brought by innovative screening tools **Prasun Mishra —** *CEO,* Agility Pharmaceuticals
18:00 - 19:00	DRINKS & CANAPES RECEPTION				

KEYNOTE PRESENTATION

Speaker
TBC

OPENING KEYNOTE PANEL SESSION | 08:30 - 09:00

Assessing the COVID-19 Impact on Drug Discovery in Medicinal Chemistry: The Industry Priorities for 2021?

- Weighing the pros and cons of rapid global therapy development to strategize for lost time and improve efficiency in 2021 and beyond
- How we utilize data integration from multiple sources to accelerate progress
- Evaluating the costs & benefits of emerging technologies
- Explore new opportunities for research and funding in 2021

Speaker
TBC

2ND KEYNOTE PRESENTATION | 13:00 - 13:30

Topic TBC

TRACK 1
Artificial Intelligence / Machine Learning

Uli Schmitz
Executive Director, Structural Chemistry
Gilead Sciences

09:00 - 10:00

Evaluating the impact of AI generative methods and ML models in drug discovery

WuXi AppTec

11:00 - 12:00 SPONSOR

Harnessing the technology of noisy intermediate-scale quantum (NISQ) in drug discovery - Title TBC

药明康德
WuXi AppTec

Bill Shirley
Senior Director, Structural Chemistry
Gilead Sciences

13:30 - 14:30

Beyond the AI hype: What has worked, and what will be improved in the future?

Speaker TBC

15:30 - 16:30 SPONSOR

Leveraging AI and ML to extract value from large, disparate, internal/ external data sets to aid drug discovery

Tudor Oprea
Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine
University of New Mexico

17:00 - 18:00

Beyond the Hype of New Machine Learning Technology and Onto Delivery

Mike Petrassi
VP, Medicinal Chemistry
Calibr/Scripps Research

09:00 - 10:00

Shifting away from the single-target paradigm: linking pharmacological data with biological pathways via high-throughput computational methods

Collaborative Drug Discovery (CDD)

11:00 - 12:00 **SPONSOR**

Discussing strategies in modeling of chemical reactions at larger scales - Title TBC

CDD VAULT®
COLLABORATIVE DRUG DISCOVERY

Speaker TBC

13:30 - 14:30

Leveraging DNA-encoded libraries and cheminformatics to discover novel reactions and chemistries

Speaker TBC

15:30 - 16:30 **SPONSOR**

Improving CADD capacities: moving past classical AI and ML towards the quantum age

Katherine Matsumoto
Director, Product Management
Recursion Pharmaceuticals

17:00 - 18:00

Evaluating the challenges surrounding obtaining and structuring the right data sets

TRACK 3
Design & Custom Synthesis

Syed Askari
President & CEO
Maculus Therapeutix

09:00 - 10:00

Optimizing autonomy in synthesis: discussing the current state and outlook towards better efficiency

Speaker TBC

11:00 - 12:00 **SPONSOR**

Furthering the new paradigm: the marriage of robotics and advanced analytics in drug design

Paul Galatsis
VP, Chemistry
Vibliome Therapeutics

13:30 - 14:30

How does the target integrate with the clinical side? What can we do to ensure success in the clinic?

Speaker TBC

15:30 - 16:30 **SPONSOR**

Innovative design & development steps to optimise outsourcing speed, reliability and cost

Speaker TBC

17:00 - 18:00

Novel computational approaches to design next gen drugs keeping optimized scale up and yield in mind

Speaker TBC

09:00 - 10:00

Novel strategies to balancing high-throughput capabilities with multi-parametric studies

Nanome

11:00 - 12:00 SPONSOR

Innovative approaches to early drug discovery through novel chemical modalities

Nanome

David Wustrow
Vice President, Discovery
RAPT Therapeutics

13:30 - 14:30

Computational Methods for Hit to Lead Optimization - how do we prioritize good from bad?

Speaker TBC

15:30 - 16:30 SPONSOR

Delineating the pros and cons of molecular dynamics simulations in fragment-based drug design

Robert Hilgraf
Senior Director, Medicinal Chemistry
REVOLUTION Medicines

17:00 - 18:00

Targeting Protein-Protein Interactions (PPIs) – Challenges and Technologies

TRACK 5
Integrated Drug Discovery

Peter Kotsonis
Executive Director,
Office of Strategic Alliances
UCSF

Ellen Kats, Ph.D
Assistant Director, Business
Development & Licensing
UCSF

(CO-HOST)

13:30 - 14:30

Partnering and Licensing with an Academic Medical Center

Speaker TBC

11:00 - 12:00 **SPONSOR**

Advancing cycle time, analysis and purification efficiency through novel technologies and innovative approaches

---

Yuhua Ji
Head of Medicinal
Chemistry
Zai Lab US

13:30 - 14:30

Effective Integration of Multidisciplinary Teams to Ensure Seamless Drug Discovery Processes

---

Speaker TBC

15:30 - 16:30 **SPONSOR**

Optimising early drug discovery through harmonised DDI testing, genetic heterogeneity and PK data analysis

---

Prasun Mishra
CEO
Agility Pharmaceuticals

17:00 - 18:00

Reinstating phenotypic screening in your drug discovery workflow: discover novel phenotypes brought by innovative screening tools